Submit Deal

SWEDISH ORPHAN BIOVITRUM AB (SOBI)

Summary

Swedish Orphan Biovitrum (SOBI) operates as a bio-pharmaceutical and bio-technology company. The Company develops therapies and drugs for the treatment of haemophilia, inflammation, and genetic diseases. SOBI serves clients worldwide.

Deals Overview

Total Deals4

Valued Deals4

Total Value£ 8.31 B

Avg. Deal Size£ 2.08 B

Market Context

Senior Management

Guido Oelkers
President and CEO
Henrik Karl Stenqvist
CFO
Hakan Bjorklund
Chairman

Senior Management

Guido Oelkers
President and CEO
Henrik Karl Stenqvist
CFO
Hakan Bjorklund
Chairman

Sort

12 Jun 2019|Switzerland|Pharmaceuticals

Target: NOVIMMUNE (EMAPALUMAB AND RELATED ASSETS)

Bidder: SWEDISH ORPHAN BIOVITRUM AB (SOBI)

9 Service Providers

6 Bidder | 3 Vendor

31 Dealmakers

13 Bidder | 18 Vendor

£ 409 M

Value

30 Sep 2019|United States|Pharmaceuticals

Target: DOVA PHARMACEUTICALS

Bidder: SWEDISH ORPHAN BIOVITRUM AB (SOBI)

9 Service Providers

5 Target | 4 Bidder

26 Dealmakers

7 Target | 19 Bidder

£ 744 M

Value

02 Sep 2021|Sweden|Biotechnology

Target: SWEDISH ORPHAN BIOVITRUM AB (SOBI)

Bidder: ADVENT INTERNATIONAL CORPORATION

16 Service Providers

4 Target | 12 Bidder

39 Dealmakers

8 Target | 31 Bidder

£ 5.81 B

Value

10 May 2023|United States|Pharmaceuticals

Target: CTI BIOPHARMA

Bidder: SWEDISH ORPHAN BIOVITRUM AB (SOBI)

16 Service Providers

7 Target | 9 Bidder

76 Dealmakers

26 Target | 51 Bidder

£ 1.35 B

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy